Methods for the therapeutic use of cyclosporine components
View Patent ↗Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporine component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter plylori infection, duodenal ulcers, peptic ulcers, conditions affecting the uterus and appendicitis.
1. A method of treating inflammatory bowel disease in a human or animal, the method comprising:
topically administering to a human or animal having inflammatory bowel disease a therapeutically effective amount of a cyclosporin A component selected from the group consisting of cyclosporin A, salts thereof and mixtures thereof, in a rectal suppository, thereby treating the inflammatory bowel disease.
2. The method of claim 1 wherein the administering step comprises topically administering the cyclosporin A component at or near a tissue area of the human or animal affected by the inflammatory bowel disease.
3. The method of claim 1 wherein the inflammatory bowel disease is ulcerative colitis.
4. The method of claim 1 wherein the cyclosporin A component is cyclosporin A.
5. The method of claim 1 wherein the treating comprises reducing the severity of at least one symptom of the inflammatory bowel disease.
6. The method of claim 1 wherein the cyclosporin A component is present in the rectal suppository in an amount of at least about 0.03% by weight.
7. The method of claim 1 wherein the cyclosporin A component is present in the rectal suppository in an amount in a range of about 0.1% to about 15% by weight.
8. A method of treating ulcerative colitis in a human or animal, the method comprising:
topically administering to a human or animal having ulcerative colitis a therapeutically effective amount of a cyclosporin A component selected from the group consisting of cyclosporin A, salts thereof and mixtures thereof, in a rectal suppository, thereby treating the ulcerative colitis.
9. The method of claim 8 wherein the administering step comprises topically administering the cyclosporin A component at or near a tissue area of the human or animal affected by the ulcerative colitis.
10. The method of claim 8 wherein the cyclosporin A component is cyclosporin A.
11. The method of claim 8 wherein the treating comprises reducing the severity of at least one symptom of the ulcerative colitis.
12. The method of claim 8 wherein the cyclosporin A component is present in the rectal suppository in an amount of at least about 0.03% by weight.
13. The method of claim 8 wherein the cyclosporin A component is present in the rectal suppository in an amount in a range of about 0.1% to about 15% by weight.